Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$35.6B
483M shares
52-week range
$61.84 – $90.41
44% from low
Exchange
NYSE
CS
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
www.alcon.comNo one on the platform currently holds ALC.
No tracked institution reports a position in ALC as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-06 | $0.2800 | 2026-05-07 |
| 2025-05-14 | $0.2800 | 2025-05-15 |
| 2024-05-14 | $0.2400 | 2024-05-16 |
No one on the platform has traded ALC yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.9B | +6.3% | $3.40 | $3.29–$3.75 | 21.8× | 16 |
| 2027 | $11.6B | +6.1% | $3.88 | $3.78–$3.99 | 19.1× | 17 |
| 2028 | $12.3B | +6.0% | $4.40 | $2.91–$5.44 | 16.9× | 15 |
| 2029 | $13.0B | +5.7% | $5.09 | $4.99–$5.23 | 14.6× | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $0.77 | $0.84 | +9.1% |
| 2026-05-05 | $0.80 | $0.85 | +6.2% |
| 2026-02-24 | $0.79 | $0.78 | -1.3% |
| 2025-11-11 | $0.77 | $0.79 | +2.6% |
| 2025-08-19 | $0.71 | $0.76 | +7.0% |
| 2025-05-13 | $0.76 | $0.73 | -3.9% |
| 2025-02-25 | $0.70 | $0.72 | +2.9% |
| 2024-11-12 | $0.72 |
| $0.81 |
| +12.5% |
| $33.3B |
| — |
| HUMHumana Inc. | $384.97 | -0.99% | $46.2B | — |
| INSMInsmed Incorporated | $126.33 | -4.50% | $27.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$NFLX $V $MA $ALC Bill Ackman's new additions: https://www.tradingview.com/news/reuters.com,2026:newsml_L6N44914Q:0-ackman-unveils-six-new-investments-including-netflix-visa-mastercard-in-biggest-portfolio-overhaul-in-years/
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-10-alcon-inc-stock/ $ALC Alcon Earnings Transcript
View on StockTwits ↗$BW $RIOT $ALC $CAH $ACVA PRE-MARKET MOVERS: Currently Higher After Earnings: - Babcock & Wilcox (BW) up 36.8% - Riot Platforms (RIOT) up 18.0% - Alcon (ALC) up 3.6% Currently Also Higher: - ACV Auctions (ACVA) up 12.5% after Bloomberg reported the company is exploring strategic alternatives, including a potential sale or strategic partnership - First Solar (FSLR) up 3.7% after Baird initiated coverage of the stock with an Outperform rating and a price target of $318 Currently Lower After Earnings: - Life360 (LIF) down 22/6% - Upwork (UPWK) down 16.1% - On Holding (ONON) down 17.7% - Hims & Hers (HIMS) down 6.8% - Rocket Lab (RKLB) down 3.1% - Cardinal Health (CAH) down 0.9% Currently Also Lower: - Intel (INTC) down 0.3% after increasing the size of its share sale to $20B in common stock from $15B
View on StockTwits ↗$ALC Positive (88%): shares should receive upward pressure as investors incorporate higher fiscal-2026 adjusted earnings and margin expectations into forward estimates. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/72731fc37230baac?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗$IR $ALC $VEEV $RJF $SHG Ingersoll Rand benefits from industrial demand, Alcon leads eye care products, Veeva dominates life sciences software, Raymond James expands wealth management, and Standard Chartered benefits from international banking.
View on StockTwits ↗Just spotted $ALC holding up well despite the Asia-Pacific softness. The margin compression is nipping at its heels, but core surgical segments are pumping cash flow. Check out the forecast and price targets in this report: https://app.k3vl4r.com/r/alc-ai-stock-forecast-0e50e31e6c8539d47f5563beb625082a?utm_source=x&utm_medium=social&utm_campaign=report_drop&utm_content=ALC #stocks #trading
View on StockTwits ↗$ALC this thing is loading up! Ready for explosive take off.
View on StockTwits ↗$ALC Fighting to retain its value, long term trend is dismal and market is waiting to see if they can recoup their golden child mojo
View on StockTwits ↗$OTLK How many opthalmic bevacizumab injections do you anticipate over 12 years combining USA and internationally? $REGN $JNJ $ALC
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.